Uses precision fermentation to produce human breast-milk proteins for infant formula
| Date | Round | Amount |
|---|---|---|
| Nov 2021 | Series A Helaina, a US biotech using precision fermentation to make human breast-milk-equivalent proteins for infant formula, raised a $20M Series A co-led by Spark Capital and Siam Capital. | $20M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.